---
document_datetime: 2025-12-29 10:33:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nodetrip.html
document_name: nodetrip.html
version: success
processing_time: 0.1682302
conversion_datetime: 2025-12-31 04:10:15.966281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nodetrip (previously Xeristar)

[RSS](/en/individual-human-medicine.xml/66057)

##### Withdrawn

This medicine's authorisation has been withdrawn

duloxetine Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nodetrip (previously Xeristar)](#news-on)
- [More information on Nodetrip (previously Xeristar)](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 12 May 2021, the European Commission withdrew the marketing authorisation for Nodetrip (duloxetine) in the EU. The withdrawal was at the request of the marketing authorisation holder, Esteve Pharmaceuticals S.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Nodetrip was granted marketing authorisation in the EU on 17 December 2004 for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2009.

The European Public Assessment Report (EPAR) for Nodetrip is updated to indicate that the marketing authorisation is no longer valid.

Nodetrip (previously Xeristar) : Medicine overview

Reference Number: EMA/559525/2020

English (EN) (682.05 KB - PDF)

**First published:** 20/11/2009

**Last updated:** 22/06/2021

[View](/en/documents/overview/nodetrip-previously-xeristar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-694)

български (BG) (749.16 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/bg/documents/overview/nodetrip-previously-xeristar-medicine-overview_bg.pdf)

español (ES) (682.3 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/es/documents/overview/nodetrip-previously-xeristar-medicine-overview_es.pdf)

čeština (CS) (722.78 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/cs/documents/overview/nodetrip-previously-xeristar-medicine-overview_cs.pdf)

dansk (DA) (680.94 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/da/documents/overview/nodetrip-previously-xeristar-medicine-overview_da.pdf)

Deutsch (DE) (685.84 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/de/documents/overview/nodetrip-previously-xeristar-medicine-overview_de.pdf)

eesti keel (ET) (670.78 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/et/documents/overview/nodetrip-previously-xeristar-medicine-overview_et.pdf)

ελληνικά (EL) (729.55 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/el/documents/overview/nodetrip-previously-xeristar-medicine-overview_el.pdf)

français (FR) (684.74 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/fr/documents/overview/nodetrip-previously-xeristar-medicine-overview_fr.pdf)

hrvatski (HR) (705.14 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/hr/documents/overview/nodetrip-previously-xeristar-medicine-overview_hr.pdf)

italiano (IT) (681.27 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/it/documents/overview/nodetrip-previously-xeristar-medicine-overview_it.pdf)

latviešu valoda (LV) (741.61 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/lv/documents/overview/nodetrip-previously-xeristar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (706.01 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/lt/documents/overview/nodetrip-previously-xeristar-medicine-overview_lt.pdf)

magyar (HU) (722.57 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/hu/documents/overview/nodetrip-previously-xeristar-medicine-overview_hu.pdf)

Malti (MT) (725.29 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/mt/documents/overview/nodetrip-previously-xeristar-medicine-overview_mt.pdf)

Nederlands (NL) (681.77 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/nl/documents/overview/nodetrip-previously-xeristar-medicine-overview_nl.pdf)

polski (PL) (724.84 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/pl/documents/overview/nodetrip-previously-xeristar-medicine-overview_pl.pdf)

português (PT) (693.56 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/pt/documents/overview/nodetrip-previously-xeristar-medicine-overview_pt.pdf)

română (RO) (702.41 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/ro/documents/overview/nodetrip-previously-xeristar-medicine-overview_ro.pdf)

slovenčina (SK) (723.55 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/sk/documents/overview/nodetrip-previously-xeristar-medicine-overview_sk.pdf)

slovenščina (SL) (721 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/sl/documents/overview/nodetrip-previously-xeristar-medicine-overview_sl.pdf)

Suomi (FI) (680.34 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/fi/documents/overview/nodetrip-previously-xeristar-medicine-overview_fi.pdf)

svenska (SV) (681.49 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

22/06/2021

[View](/sv/documents/overview/nodetrip-previously-xeristar-medicine-overview_sv.pdf)

Xeristar - EPAR - Risk-management-plan summary

English (EN) (817.27 KB - PDF)

**First published:** 08/10/2019

**Last updated:** 22/06/2021

[View](/en/documents/rmp-summary/xeristar-epar-risk-management-plan-summary_en.pdf)

## Product information

Nodetrip : EPAR - Product Information

English (EN) (793.23 KB - PDF)

**First published:** 17/08/2009

**Last updated:** 22/06/2021

[View](/en/documents/product-information/nodetrip-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-971)

български (BG) (1.14 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/bg/documents/product-information/nodetrip-epar-product-information_bg.pdf)

español (ES) (845.16 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/es/documents/product-information/nodetrip-epar-product-information_es.pdf)

čeština (CS) (1.07 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/cs/documents/product-information/nodetrip-epar-product-information_cs.pdf)

dansk (DA) (803.66 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/da/documents/product-information/nodetrip-epar-product-information_da.pdf)

Deutsch (DE) (802.9 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/de/documents/product-information/nodetrip-epar-product-information_de.pdf)

eesti keel (ET) (847.23 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/et/documents/product-information/nodetrip-epar-product-information_et.pdf)

ελληνικά (EL) (1.12 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/el/documents/product-information/nodetrip-epar-product-information_el.pdf)

français (FR) (924.45 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/fr/documents/product-information/nodetrip-epar-product-information_fr.pdf)

hrvatski (HR) (971.91 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/hr/documents/product-information/nodetrip-epar-product-information_hr.pdf)

íslenska (IS) (826.56 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/is/documents/product-information/nodetrip-epar-product-information_is.pdf)

italiano (IT) (862.17 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/it/documents/product-information/nodetrip-epar-product-information_it.pdf)

latviešu valoda (LV) (1.04 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/lv/documents/product-information/nodetrip-epar-product-information_lv.pdf)

lietuvių kalba (LT) (987.92 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/lt/documents/product-information/nodetrip-epar-product-information_lt.pdf)

magyar (HU) (1.02 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/hu/documents/product-information/nodetrip-epar-product-information_hu.pdf)

Malti (MT) (1.06 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/mt/documents/product-information/nodetrip-epar-product-information_mt.pdf)

Nederlands (NL) (819.45 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/nl/documents/product-information/nodetrip-epar-product-information_nl.pdf)

norsk (NO) (823.65 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/no/documents/product-information/nodetrip-epar-product-information_no.pdf)

polski (PL) (1.04 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/pl/documents/product-information/nodetrip-epar-product-information_pl.pdf)

português (PT) (892.28 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/pt/documents/product-information/nodetrip-epar-product-information_pt.pdf)

română (RO) (1016.84 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/ro/documents/product-information/nodetrip-epar-product-information_ro.pdf)

slovenčina (SK) (1.02 MB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/sk/documents/product-information/nodetrip-epar-product-information_sk.pdf)

slovenščina (SL) (1016.38 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/sl/documents/product-information/nodetrip-epar-product-information_sl.pdf)

Suomi (FI) (819.54 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/fi/documents/product-information/nodetrip-epar-product-information_fi.pdf)

svenska (SV) (803.62 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

22/06/2021

[View](/sv/documents/product-information/nodetrip-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WITHDRAWAL 12/05/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nodetrip (previously Xeristar) : EPAR - All Authorised presentations

English (EN) (579.72 KB - PDF)

**First published:** 13/03/2019

**Last updated:** 22/06/2021

[View](/en/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-659)

български (BG) (651.64 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/bg/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_bg.pdf)

español (ES) (579.12 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/es/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_es.pdf)

čeština (CS) (603.98 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/cs/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (578.85 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/da/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (579.59 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/de/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (581.03 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/et/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (625.04 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/el/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_el.pdf)

français (FR) (579.35 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/fr/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (599.41 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/hr/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (582.84 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/is/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_is.pdf)

italiano (IT) (579.38 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/it/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (616.63 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/lv/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (602.72 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/lt/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (614.29 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/hu/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (612.43 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/mt/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (581.01 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/nl/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (579.04 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/no/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_no.pdf)

polski (PL) (615.42 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/pl/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_pl.pdf)

português (PT) (579.12 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/pt/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_pt.pdf)

română (RO) (594.98 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/ro/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (603.19 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/sk/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (611.31 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/sl/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (581.54 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/fi/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (579.6 KB - PDF)

**First published:**

13/03/2019

**Last updated:**

22/06/2021

[View](/sv/documents/all-authorised-presentations/nodetrip-previously-xeristar-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nodetrip (previously Xeristar) Active substance duloxetine International non-proprietary name (INN) or common name duloxetine Therapeutic area (MeSH)

- Anxiety Disorders
- Depressive Disorder, Major
- Diabetic Neuropathies

Anatomical therapeutic chemical (ATC) code N06AX21

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

- Treatment of major depressive disorder;
- Treatment of diabetic peripheral neuropathic pain;
- Treatment of generalised anxiety disorder;
- Xeristar is indicated in adults.

## Authorisation details

EMA product number EMEA/H/C/000573 Marketing authorisation holder

Esteve Pharmaceuticals, S.A.

Passeig de la Zona Franca, 109 Planta 4 08038 Barcelona Spain

Opinion adopted 16/09/2004 Marketing authorisation issued 17/12/2004 Withdrawal of marketing authorisation 12/05/2021 Revision 32

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nodetrip (previously Xeristar) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (832.28 KB - PDF)

**First published:** 17/08/2009

**Last updated:** 22/06/2021

[View](/en/documents/procedural-steps-after/nodetrip-previously-xeristar-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Xeristar-H-C-PSUSA-00001187-201408 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/PRAC/154100/2015

English (EN) (622.5 KB - PDF)

**First published:** 26/10/2015

**Last updated:** 22/06/2021

[View](/en/documents/scientific-conclusion/xeristar-h-c-psusa-00001187-201408-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xeristar-H-C-573-P46-P45-045.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/121591/2013

English (EN) (2.66 MB - PDF)

**First published:** 08/03/2013

**Last updated:** 22/06/2021

[View](/en/documents/variation-report/xeristar-h-c-573-p46-p45-0451-epar-assessment-report_en.pdf)

Xeristar-H-C-573-P46-0040 : EPAR - Assessment Report

Adopted

Reference Number: EMA/18171/2013

English (EN) (1 MB - PDF)

**First published:** 17/01/2013

**Last updated:** 22/06/2021

[View](/en/documents/variation-report/xeristar-h-c-573-p46-0040-epar-assessment-report_en.pdf)

Xeristar-H-C-573-WS-0076 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/285264/2012

English (EN) (1.54 MB - PDF)

**First published:** 13/06/2012

**Last updated:** 22/06/2021

[View](/en/documents/variation-report/xeristar-h-c-573-ws-0076-epar-assessment-report-variation_en.pdf)

Questions and answers on the refusal of a change to the marketing authorisations for Ariclaim, Cymbalta and Xeristar (duloxetine) - Outcome of re-examination

Adopted

Reference Number: EMA/901723/2011

English (EN) (513 KB - PDF)

**First published:** 18/11/2011

**Last updated:** 22/06/2021

[View](/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_en.pdf)

[Other languages (21)](#file-language-dropdown-356)

български (BG) (613.62 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_bg.pdf)

español (ES) (514.39 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_es.pdf)

čeština (CS) (582.79 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_cs.pdf)

dansk (DA) (514.25 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_da.pdf)

Deutsch (DE) (517.01 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_de.pdf)

eesti keel (ET) (513.23 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_et.pdf)

ελληνικά (EL) (623.44 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_el.pdf)

français (FR) (514.54 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_fr.pdf)

italiano (IT) (577.69 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_it.pdf)

latviešu valoda (LV) (587.08 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_lv.pdf)

lietuvių kalba (LT) (544.26 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_lt.pdf)

magyar (HU) (574.38 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_hu.pdf)

Malti (MT) (581.85 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_mt.pdf)

Nederlands (NL) (513.34 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_nl.pdf)

polski (PL) (580.11 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_pl.pdf)

português (PT) (512.74 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_pt.pdf)

română (RO) (537.43 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_ro.pdf)

slovenčina (SK) (655.65 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_sk.pdf)

slovenščina (SL) (652.72 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_sl.pdf)

Suomi (FI) (514.1 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_fi.pdf)

svenska (SV) (612.7 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

22/06/2021

[View](/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisations-ariclaim-cymbalta-and-xeristar-duloxetine-outcome-re-examination_sv.pdf)

Questions and answers on the refusal of a change to the marketing authorisation for Ariclaim, Cymbalta and Xeristar

Adopted

Reference Number: EMA/CHMP/580268/2011

English (EN) (496.52 KB - PDF)

**First published:** 22/07/2011

**Last updated:** 07/08/2018

[View](/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_en.pdf)

[Other languages (21)](#file-language-dropdown-852)

български (BG) (613.55 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_bg.pdf)

español (ES) (514.39 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_es.pdf)

čeština (CS) (582.79 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_cs.pdf)

dansk (DA) (514.25 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_da.pdf)

Deutsch (DE) (517.02 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_de.pdf)

eesti keel (ET) (513.25 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_et.pdf)

ελληνικά (EL) (623.45 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_el.pdf)

français (FR) (514.55 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_fr.pdf)

italiano (IT) (577.7 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_it.pdf)

latviešu valoda (LV) (587.07 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_lv.pdf)

lietuvių kalba (LT) (544.27 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_lt.pdf)

magyar (HU) (574.42 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_hu.pdf)

Malti (MT) (581.86 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_mt.pdf)

Nederlands (NL) (513.33 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_nl.pdf)

polski (PL) (580.11 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_pl.pdf)

português (PT) (512.74 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_pt.pdf)

română (RO) (537.44 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_ro.pdf)

slovenčina (SK) (577.52 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_sk.pdf)

slovenščina (SL) (574.43 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_sl.pdf)

Suomi (FI) (514.1 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_fi.pdf)

svenska (SV) (513.11 KB - PDF)

**First published:**

22/07/2011

**Last updated:**

07/08/2018

[View](/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-ariclaim-cymbalta-and-xeristar_sv.pdf)

Questions and answers on recommendation for the refusal of a change to the marketing authorisation for Cymbalta / Xeristar

Adopted

Reference Number: EMEA/551181/2008

English (EN) (593.45 KB - PDF)

**First published:** 23/10/2008

**Last updated:** 22/06/2021

[View](/en/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_en.pdf)

[Other languages (21)](#file-language-dropdown-22)

български (BG) (748.33 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/bg/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_bg.pdf)

español (ES) (594.71 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/es/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_es.pdf)

čeština (CS) (692.79 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/cs/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_cs.pdf)

dansk (DA) (594.19 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/da/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_da.pdf)

Deutsch (DE) (593.79 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/de/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_de.pdf)

eesti keel (ET) (593.94 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/et/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_et.pdf)

ελληνικά (EL) (745.74 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/el/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_el.pdf)

français (FR) (594.41 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/fr/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_fr.pdf)

italiano (IT) (594.41 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/it/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_it.pdf)

latviešu valoda (LV) (712.89 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/lv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_lv.pdf)

lietuvių kalba (LT) (672.48 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/lt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_lt.pdf)

magyar (HU) (683.94 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/hu/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_hu.pdf)

Malti (MT) (722.16 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/mt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_mt.pdf)

Nederlands (NL) (594.53 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/nl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_nl.pdf)

polski (PL) (694.47 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/pl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_pl.pdf)

português (PT) (594.79 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/pt/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_pt.pdf)

română (RO) (672.41 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/ro/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_ro.pdf)

slovenčina (SK) (690.35 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/sk/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_sk.pdf)

slovenščina (SL) (683.86 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/sl/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_sl.pdf)

Suomi (FI) (594.31 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/fi/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_fi.pdf)

svenska (SV) (594.1 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

22/06/2021

[View](/sv/documents/smop/questions-and-answers-recommendation-refusal-change-marketing-authorisation-cymbalta-xeristar_sv.pdf)

Xeristar-H-C-573-II-0026 : EPAR - Refusal assessment report - Variation

English (EN) (2.77 MB - PDF)

**First published:** 23/10/2008

**Last updated:** 22/06/2021

[View](/en/documents/variation-report/xeristar-h-c-573-ii-0026-epar-refusal-assessment-report-variation_en.pdf)

Xeristar-H-C-573-II-0027 : EPAR - Assessment Report - Variation

English (EN) (905.79 KB - PDF)

**First published:** 18/09/2008

**Last updated:** 22/06/2021

[View](/en/documents/variation-report/xeristar-h-c-573-ii-0027-epar-assessment-report-variation_en.pdf)

CHMP post authorisation summary of positive opinion for Xeristar on 26 June 2008

Adopted

Reference Number: EMEA/CHMP/335994/2008

English (EN) (586.77 KB - PDF)

**First published:** 26/06/2008

**Last updated:** 22/06/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xeristar-26-june-2008_en.pdf)

Xeristar-H-C-573-II-0004 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (791.96 KB - PDF)

**First published:** 07/02/2006

**Last updated:** 22/06/2021

[View](/en/documents/scientific-discussion-variation/xeristar-h-c-573-ii-0004-epar-scientific-discussion-variation_en.pdf)

Xeristar-573-H-C-A18-652 : EPAR - Scientific Conclusion

Adopted

English (EN) (681.31 KB - PDF)

**First published:** 07/02/2006

**Last updated:** 22/06/2021

[View](/en/documents/scientific-conclusion/xeristar-573-h-c-a18-652-epar-scientific-conclusion_en.pdf)

## Initial marketing authorisation documents

Xeristar : EPAR - Procedural steps taken before authorisation

English (EN) (652.13 KB - PDF)

**First published:** 07/02/2006

**Last updated:** 22/06/2021

[View](/en/documents/procedural-steps/xeristar-epar-procedural-steps-taken-authorisation_en.pdf)

Xeristar : EPAR - Scientific Discussion

English (EN) (981.64 KB - PDF)

**First published:** 07/02/2006

**Last updated:** 22/06/2021

[View](/en/documents/scientific-discussion/xeristar-epar-scientific-discussion_en.pdf)

#### News on Nodetrip (previously Xeristar)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 November 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-november-2011) 18/11/2011

#### More information on Nodetrip (previously Xeristar)

- [EMEA-000420-PIP01-10 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000420-pip01-10)

**This page was last updated on** 22/06/2021

## Share this page

[Back to top](#main-content)